Schwab Charles Investment Management Inc. increased its position in Dermira Inc (NASDAQ:DERM) by 20.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 180,235 shares of the biopharmaceutical company’s stock after acquiring an additional 30,244 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.43% of Dermira worth $5,013,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DERM. Point72 Asset Management L.P. grew its holdings in shares of Dermira by 621.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after acquiring an additional 614,138 shares during the period. State Street Corp grew its holdings in Dermira by 38.4% during the 2nd quarter. State Street Corp now owns 821,748 shares of the biopharmaceutical company’s stock valued at $23,946,000 after buying an additional 228,093 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Dermira during the 3rd quarter valued at $3,107,000. Ameriprise Financial Inc. acquired a new stake in Dermira during the 3rd quarter valued at $2,689,000. Finally, AXA grew its holdings in Dermira by 41.5% during the 3rd quarter. AXA now owns 300,333 shares of the biopharmaceutical company’s stock valued at $8,109,000 after buying an additional 88,079 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.
In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction on Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Christopher M. Griffith sold 18,458 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,758 shares of company stock worth $810,479. Corporate insiders own 13.30% of the company’s stock.
Shares of Dermira Inc (DERM) opened at $10.26 on Thursday. Dermira Inc has a fifty-two week low of $8.55 and a fifty-two week high of $36.38. The company has a market capitalization of $428.67, a price-to-earnings ratio of -1.39 and a beta of 0.86. The company has a current ratio of 5.28, a quick ratio of 5.28 and a debt-to-equity ratio of 1.87.
Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.09). Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. The business had revenue of $1.34 million for the quarter, compared to analysts’ expectations of $1.10 million. equities research analysts forecast that Dermira Inc will post -4.66 earnings per share for the current year.
WARNING: This piece was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://weekherald.com/2018/03/15/schwab-charles-investment-management-inc-grows-position-in-dermira-inc-derm.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.